Oncologist Reviews The FDA-Avastin Decision
 

Controversy over the F.D.A.'s proposal to withdraw approval of Avastin (bevacizumab) for breast cancer treatment will reignite June 28-29 with a new round of hearings. One oncologist who will be monitoring the hearings is Dr. Frederick C. Tucker Jr. of Fredericksburg Oncology in Virginia, whose recent New York Times op ed defended the F.D.A.'s position on scientific grounds. Dr...

More...

Re: Oncologist Reviews The FDA-Avastin Decision